Instructor, Surgery, Massachusetts General Hospital, Harvard Medical School
General Surgery
Dr. Jennifer A. Wargo, MD
|
|
Give Review
Jennifer A. Wargo, MD practices General Surgery. He graduated from University Hospital - University of Cincinnati College of Medicine. He has 1 awards "Fellow (FACS)". Dr. Jennifer A. Wargo is also published. He has 66 publications published. The lastest publication: "MITF Modulates Therapeutic Resistance through EGFR Signaling.'
Publications
- The Hippo effector YAP promotes resistance to RAF- and MEK-targeted Cancer therapies.
- Use of clinical next-generation sequencing to identify melanomas harboring SMARCB1 mutations.
- MITF Modulates Therapeutic Resistance through EGFR Signaling.
- Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma.
- EphA2 is a Mediator of Vemurafenib Resistance and a Novel Therapeutic Target in Melanoma.
- Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation.
- Universes Collide: Combining Immunotherapy with Targeted Therapy for Cancer.
- Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and Oxidative Phosphorylation in melanoma.
- Clinical utility of a blood-based BRAF V600E mutation assay in melanoma.
- A potential role for immunotherapy in thyroid Cancer by enhancing NY-ESO-1 Cancer antigen expression.
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade.
- PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation.
- Potential role of 5-Aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid Cancer.
- A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.
- MAP Kinase Pathway Alterations in BRAF-Mutant Melanoma Patients with Acquired Resistance to Combined RAF/MEK Inhibition.
- Hypoxia Induces Phenotypic Plasticity and Therapy Resistance in Melanoma via the Tyrosine Kinase Receptors ROR1 and ROR2.
- Surgery for Small and Asymptomatic Branch-Duct IPMNs.
- BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes.
- Understanding Hospital Readmissions After Pancreaticoduodenectomy: Can We Prevent Them? : A 10-Year Contemporary Experience with 1,173 Patients at the Massachusetts Ge...
- TORC1 Suppression Predicts Responsiveness to RAF and MEK Inhibition in BRAF-Mutant Melanoma.
- Case records of the Massachusetts General Hospital. Case 21-2013. A 68-year-old man with metastatic melanoma.
- BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition.
- Oncogenic BRAF Regulates Oxidative Metabolism via PGC1? and MITF.
- Elucidating Distinct Roles for NF1 in Melanomagenesis.
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice.
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma.
- N0/N1, PNL, or LNR? The Effect of Lymph Node Number on Accurate Survival Prediction in Pancreatic Ductal Adenocarcinoma.
- An ultraviolet-radiation-independent pathway to melanoma carcinogenesis in the red hair/fair skin background.
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma.
- Pancreatic Ductal Adenocarcinoma: Is There a Survival Difference for R1 Resections Versus Locally Advanced Unresectable Tumors? What Is a "True" R0 Resection?
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via InDuction of Interleukin-1 in Melanoma.
- A landscape of driver mutations in melanoma.
- Targeting the MAGE A3 antigen in pancreatic Cancer.
- 851 resected cystic Tumors of the pancreas: A 33-year experience at the Massachusetts General Hospital.
- Evolution of the Whipple procedure at the Massachusetts General Hospital.
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion.
- Pancreatic Ductal adenocarcinoma: Long-term survival does not equal cure.
- Intraductal papillary mucinous neoplasms: Does a family history of pancreatic Cancer matter?
- EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal Cancers to RAF inhibition with vemurafenib.
- Twenty-three years of the warshaw operation for distal pancreatectomy with preservation of the spleen.
- Implications of Incidentally Discovered, Nonfunctioning Pancreatic Endocrine Tumors: Short-term and Long-term Patient Outcomes.
- A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of Cancer.
- Metastatic Tumors in the pancreas in the modern era.
- Ocular melanoma metastatic to the pancreas after a 28-year Disease-free interval.
- Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.
- Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
- Does the mechanism of lymph node invasion affect survival in patients with pancreatic Ductal adenocarcinoma?
- Surgical management of melanoma.
- Management of Pancreatic serous cystadenomas.
- Assessment of Pancreatic tumor resectability with multidetector computed tomography: semiautomated console-generated images versus dedicated workstation-generated images.
- Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.
- Small bowel Obstruction: the value of coronal reformatted images from 16-multidetector computed tomography--a clinicoradiological perspective.
- Errant central line placement.
- Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
- Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
- The status of gene therapy for surgical Disease.
- Systematic identification of signaling pathways with potential to confer antiCancer drug resistance.
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E).
- Incidental Pancreatic cysts: do we really know what we are watching?
- Recognition of NY-ESO-1+ tumor cells by engineered lymphocytes is enhanced by improved vector design and epigenetic modulation of tumor antigen expression.
- Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells.
- Surgical approach to Pancreatic exocrine neoplasms.
- Superior prognostic importance of perineural invasion vs. lymph node involvement after curative resection of duodenal adenoCarcinoma.
- Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics.
Schools
Medical College of Pennsylvania
Massachusetts General Hospital
NihNci
Procedures Preformed
- Adrenalectomy
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Excision of Bile Duct Tumor
- Excision of Breast Tumor
- View All
Conditions Treated
- Abdominal Pain
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Atelectasis
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Blue Card PPO
- Blue Choice
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Commercial Insurance Company
- Fallon Community Health Plan
- First Health (Coventry Health Care) PPO
- Harvard Pilgrim Health Care PPO
- Medicare MCR
- MHealth Insured
- Network Health
- Principal Life
- Choice Plus POS
- Navigate POS
- Options PPO
- United Healthcare
Awards
- Fellow (FACS)
Education
-
Massachusetts General Hospital -
University Hospital - University of Cincinnati College of Medicine -
University of Cincinnati College of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1861465437 |
| Last Name Of The Provider | WARGO |
| First Name Of The Provider | JENNIFER |
| View All |
Similar Doctors
|
|
Dr. Barbara L. Smith, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tsafrir Vanounou, MD |
|
|
Dr. David A. Gloth, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anthony D. Whittemore, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marissa A. Wagner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew P. Savary, MD |
|
|
Dr. Mustapha Daouadi, MD |
|
|
Dr. Rachel A. Greenup, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joaquim M. Havens, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Blea, MD
This Doctor is OpenDoctor Recommended.
|